CJC-1295 Dosage Chart
Separates with-DAC human evidence from no-DAC clinic protocols, including common ipamorelin pairing and reconstitution math.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog sold in two forms: 'with DAC' (Drug Affinity Complex — long half-life, sustained GH elevation) and 'no DAC' (also called Mod GRF 1-29 — short-acting, used in clinic protocols to target pulses). The cited human studies are with-DAC studies. No-DAC schedules and no-DAC + ipamorelin pairing are clinic/vendor convention, not protocols established by those with-DAC papers.
CJC-1295 at a Glance
| With DAC — common clinic/vendor dose | 1–2 mg subQ, 1–2× per week |
|---|---|
| No DAC (Mod GRF 1-29) — clinic/vendor dose | 100 mcg subQ, 1–3× per day |
| Common pairing | No-DAC CJC-1295 + ipamorelin (typically 100 mcg of each; clinic convention) |
| Cycle length | 8–12 weeks on, 4 weeks off (clinic convention) |
| Best timing | Pre-bed (90+ minutes after last meal) and/or fasted morning |
| FDA status | Not FDA-approved. Compounded; cited human studies are with-DAC pharmacodynamic studies, not FDA-label dosing. |
| Source quality | Human data are with-DAC CJC-1295; no-DAC and combo protocols are practitioner-derived. |
CJC-1295 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for CJC-1295. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 2 mg (no DAC) | 2 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
| 2 mg (with DAC) | 2 mL | 1 mg/mL |
|
| 5 mg (combination CJC/ipamorelin blend) | 2.5 mL | 2 mg/mL combined |
|
U-100 syringe reference: 100 units = 1.0 mL. So 10 units = 0.1 mL, 25 units = 0.25 mL, 50 units = 0.5 mL. Pre-mixed CJC-1295 + ipamorelin blend vials are common at compounding pharmacies — confirm the per-component concentration on your label before drawing.
CJC-1295 Dosing by Use Case
Commonly cited protocols vary by what CJC-1295 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Pulsatile GH support (no-DAC, with ipamorelin; clinic convention) | 100 mcg CJC-1295 + 100 mcg ipamorelin | Pre-bed, 5–7 nights per week | 8–12 weeks | Common 'CJC/Ipa' clinic protocol; not established by the cited with-DAC studies. |
| Multi-dose pulsatile (no-DAC; clinic convention) | 100 mcg CJC-1295 + 100 mcg ipamorelin | 2–3× daily (AM fasted, post-workout, pre-bed) | 8–12 weeks | Higher compliance burden; not trial-derived. |
| Sustained GH elevation (with DAC) | 1–2 mg CJC-1295 with DAC | 1–2× per week | 8–12 weeks | Common clinic/vendor schedule; cited with-DAC studies used weight-based dosing and do not establish this fixed-dose protocol. |
Stacking CJC-1295
In compounded clinic practice, the dominant CJC-1295 protocol is the no-DAC version paired with ipamorelin, often supplied as pre-mixed CJC/Ipa blend vials. The cited with-DAC papers do not test that no-DAC + ipamorelin stack. CJC-1295 with DAC is less often paired with ipamorelin because its sustained activity does not match the short-pulse rationale for the stack.
Where these numbers come from
The cited CJC-1295 studies are human studies of the long-acting with-DAC formulation, including weight-based subcutaneous dosing and sustained GH/IGF-I pharmacodynamics in healthy adults. With-DAC CJC-1295 and no-DAC Mod GRF 1-29 are pharmacologically different; a with-DAC study does not establish a no-DAC protocol or the no-DAC + ipamorelin combination. The fixed 100 mcg no-DAC, CJC/Ipa blend, 8-12 week cycle, and 1-2 mg with-DAC clinic schedules shown here are practitioner/vendor convention, not FDA-label dosing.
Cited with-DAC studies reported tolerability, but off-label no-DAC and combo protocols have limited human safety data.
- •Common side effects: injection-site reactions, mild fluid retention, transient flushing or headache, vivid dreams.
- •With-DAC concern: sustained elevation with higher trough GH differs from normal low-trough pulsatility. Long-term implications are not well-studied.
- •Theoretical concern with chronic GH elevation: insulin resistance, water retention, possible facilitation of cancer growth in patients with malignancy. Not unique to CJC-1295 — applies to all GH-releasing peptides.
- •Human safety data for no-DAC and CJC/Ipa clinic protocols is limited.
- •Active or recent malignancy
- •Untreated hyperglycemia or poorly controlled diabetes
- •Pregnancy or breastfeeding
- •Children or adolescents (use only under specialist supervision for diagnosed GH deficiency)
CJC-1295 Dosing FAQ
DAC stands for Drug Affinity Complex, a chemical modification used in the long-acting formulation studied in humans. With-DAC produces sustained GH elevation; no-DAC (Mod GRF 1-29) is marketed and used as a short-acting peptide in clinic protocols. The cited with-DAC studies do not establish no-DAC pharmacokinetics or dosing.
The clinic-practice rationale is to combine GHRH-receptor signaling from no-DAC CJC-1295/Mod GRF with ghrelin-receptor signaling from ipamorelin. This chart does not cite a human trial testing the combination or proving a specific combined dose.
Pre-bed dosing (90+ minutes after the last meal, ideally on an empty stomach) is the most common clinic-convention single-dose schedule because it aims to align with overnight GH physiology. Multi-dose protocols add a fasted morning dose and/or post-workout dose, but those schedules are not established by the cited with-DAC studies.
Any sleep, recovery, body-composition, skin, or anti-aging timelines are practitioner- and patient-reported. The cited with-DAC papers measured pharmacodynamic markers such as GH and IGF-I, not validated outcome timelines for no-DAC or CJC/Ipa protocols.
Sources
Related Dosage Charts
Want the full CJC-1295 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for CJC-1295 therapy.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.